241 related articles for article (PubMed ID: 29042487)
1. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.
Bell JB; Eckerdt F; Dhruv HD; Finlay D; Peng S; Kim S; Kroczynska B; Beauchamp EM; Alley K; Clymer J; Goldman S; Cheng SY; James CD; Nakano I; Horbinski C; Mazar AP; Vuori K; Kumthekar P; Raizer J; Berens ME; Platanias LC
Mol Cancer Res; 2018 Jan; 16(1):32-46. PubMed ID: 29042487
[TBL] [Abstract][Full Text] [Related]
2. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
Bell JB; Eckerdt FD; Alley K; Magnusson LP; Hussain H; Bi Y; Arslan AD; Clymer J; Alvarez AA; Goldman S; Cheng SY; Nakano I; Horbinski C; Davuluri RV; James CD; Platanias LC
Mol Cancer Res; 2016 Oct; 14(10):984-993. PubMed ID: 27364770
[TBL] [Abstract][Full Text] [Related]
3. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
5. Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
Dolniak B; Katsoulidis E; Carayol N; Altman JK; Redig AJ; Tallman MS; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Platanias LC
J Biol Chem; 2008 May; 283(18):12034-42. PubMed ID: 18299328
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
[TBL] [Abstract][Full Text] [Related]
7. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
9. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.
Mao P; Joshi K; Li J; Kim SH; Li P; Santana-Santos L; Luthra S; Chandran UR; Benos PV; Smith L; Wang M; Hu B; Cheng SY; Sobol RW; Nakano I
Proc Natl Acad Sci U S A; 2013 May; 110(21):8644-9. PubMed ID: 23650391
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
12. The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
Tumour Biol; 2014 May; 35(5):4567-80. PubMed ID: 24399651
[TBL] [Abstract][Full Text] [Related]
13. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract][Full Text] [Related]
14. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.
Gao Z; Xu J; Fan Y; Zhang Z; Wang H; Qian M; Zhang P; Deng L; Shen J; Xue H; Zhao R; Zhou T; Guo X; Li G
J Exp Clin Cancer Res; 2022 Nov; 41(1):323. PubMed ID: 36380368
[TBL] [Abstract][Full Text] [Related]
15. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
16. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
[TBL] [Abstract][Full Text] [Related]
18. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
19. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.
Balasubramaniyan V; Vaillant B; Wang S; Gumin J; Butalid ME; Sai K; Mukheef F; Kim SH; Boddeke HW; Lang F; Aldape K; Sulman EP; Bhat KP; Colman H
Oncotarget; 2015 Oct; 6(31):31007-17. PubMed ID: 26307681
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
